594 related articles for article (PubMed ID: 26401690)
1. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
[TBL] [Abstract][Full Text] [Related]
2. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
3. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB
Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker.
Massa F; Farotti L; Eusebi P; Capello E; Dottorini ME; Tranfaglia C; Bauckneht M; Morbelli S; Nobili F; Parnetti L
J Alzheimers Dis; 2019; 72(4):1193-1207. PubMed ID: 31683477
[TBL] [Abstract][Full Text] [Related]
5. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
6. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
7. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
Dukart J; Sambataro F; Bertolino A
J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
[TBL] [Abstract][Full Text] [Related]
8. Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment.
Auning E; Selnes P; Grambaite R; Šaltytė Benth J; Haram A; Løvli Stav A; Bjørnerud A; Hessen E; Hol PK; Muftuler løndalen A; Fladby T; Aarsland D
Acta Psychiatr Scand; 2015 Feb; 131(2):139-47. PubMed ID: 25346330
[TBL] [Abstract][Full Text] [Related]
9. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
Schmand B; Eikelenboom P; van Gool WA;
J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
[TBL] [Abstract][Full Text] [Related]
10. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
[TBL] [Abstract][Full Text] [Related]
11. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
[TBL] [Abstract][Full Text] [Related]
12. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
13. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
Hatashita S; Yamasaki H
PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
[TBL] [Abstract][Full Text] [Related]
14. Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers.
Ivanoiu A; Dricot L; Gilis N; Grandin C; Lhommel R; Quenon L; Hanseeuw B
J Alzheimers Dis; 2015; 43(3):835-47. PubMed ID: 25114071
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
[TBL] [Abstract][Full Text] [Related]
16. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
[TBL] [Abstract][Full Text] [Related]
20. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
